IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 20/01/2020 - Institutional news

    Dr. Joaquín Arribas, new PSMAR research director and IMIM director

    Joaquín Arribas is an ICREA Research Professor at the Vall d'Hebron Institute of Oncology (VHIO) and Scientific Director at CIBERONC. He studied biochemistry at the Universidad Autónoma de Madrid (1987) where he later worked on the regulation of proteasome catalytic activities and got his PhD in Biology (1991). Sponsored by a grant from the Ministry of Education and Science, he joined the Memorial Sloan-Kettering Cancer Center in New York (USA) as a postdoctoral fellow with Joan Massagué (1992-96), where he worked on the proteolytic processing of transmembrane growth factors. In 1997 he joined the Department of Oncological Research at Vall d'Hebron Hospital in Barcelona, since which time he has been directing the Growth Factors group. In 2010, he was appointed director of the VHIO preclinical research programme, and in 2017 he became the scientific director at CIBERONC. His research has been recognised by the EMBO Young Investigator Programme Beckman Coultek Award, given to the best Spanish researcher in Biochemistry and Molecular Biology.

    Més informació "Dr. Joaquín Arribas, new PSMAR research director and IMIM director"

  • 16/12/2019 - Press release

    Hospital costs estimated of occupational diseases not recognized by the Social Security

    A new study has estimated the exact, individualized cost of healthcare for patients being treated in hospital for an occupational disease not recognized by the Social Security. The study was conducted by researchers from the Center for Research in Occupational Health (CiSAL) at Pompeu Fabra University (UPF), the Hospital del Mar Medical Research Institute (IMIM) and the Occupational Health Service at Hospital del Mar  As in other countries, Spain has two public health systems. On the one hand, the National Health Service, financed by taxes, covering all residents. On the other hand, the Social Security System is specific for occupational diseases, administered primarily by the mutual insurance companies that collaborate with the Social Security system, funded by contributions by employees and employers, which only offers protection to employees affiliated to the Social Security system.

    Més informació "Hospital costs estimated of occupational diseases not recognized by the Social Security"

  • 27/11/2019 - Press release

    Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)

    Outstanding women researchers who use the latest computer advances for biomedical research and directives from companies and institutions in the world of technology and biomedicine will present the latest developments in this field of research and discuss the most immediate challenges at the end of November in Barcelona. The meeting will take place during the first edition of the Advances in Computational Biology (AdvCompBio) conference, which will gather around 200 attendees in the auditorium of La Pedrera in Barcelona on November 28 and 29. In this conference, all speakers and organizers are women, although the sessions will be open to everyone. AdvCompBio is primarily a high-level international scientific meeting, intended to discuss the latest artificial intelligence and big data technologies in computational biology, promote the exchange of experiences and create collaborative networks.

    Més informació "Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)"

  • 06/11/2019 - Press release

    Prenatal Exposure to Air Pollution Linked to Brain Changes Associated with Behavioural Problems in Children

    Over the past few decades, various studies have investigated the impact of air pollution on cognitive capacities in children. However, very little research has been done on the changes that air pollution could induce in children's growing brains . A new study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa", with the participation of Dr. Jesús Pujol, the research director of the Hospital del Mar Magnetic Resonance Unit and researcher at the Hospital del Mar Medical Research Institute (IMIM) who carried out the magnetic resonance imaging studies, with the participation of Dr. Jesús Pujol, has found a link between air pollution and changes in the corpus callosum, a region of the brain associated with neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The study was carried out as a part of BREATHE, a project whose earlier findings suggest that air pollution has harmful effects on cognitive functions in schoolchildren and is also associated with functional changes in the brain.

    Més informació "Prenatal Exposure to Air Pollution Linked to Brain Changes Associated with Behavioural Problems in Children"

  • 29/10/2019 - Institutional news

    Living in a noisy area increases the risk of suffering a more serious stroke

    The high levels of environmental noise we are subjected to in large cities can increase both the severity and consequences of an ischaemic stroke. More precisely, researchers from the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, together with researchers from the Barcelona Institute for Global Health (ISGlobal), CIBER in Epidemiology and Public Health (CIBERESP), and Brown University, in the United States, put the increased risk at 30% for people living in noisier areas. In contrast, living close to green areas brings down this risk by up to 25%. This is the first time that these factors have been analysed in relation to stroke severity. The study has been published in the journal Environmental Research.

    Més informació "Living in a noisy area increases the risk of suffering a more serious stroke"

  • 02/10/2019 - Press release

    Our health is increasingly conditioned and at risk from the proliferation of plastics that surround us, especially for food packaging (Press release by Rezero)

    It is an initiative with no precedents, 20 relevant people of Catalonia and Balearic Island ask for tackling with urgency the crisis of plastic waste after checking the presence of plastic in its body derived from plasticized food in the entire distribution chain and consumption. Rezero collected 20 urine samples from 20 participants.Once samples were collected, samples were analyzed from Norwegian Institute of Public Health (www.fhi.no/en), referencelaboratory at international level on the detection of metabolic plastic in human samples. Specifically, it have been analyzed the presence of 27 components related to plastic exposition: 15 phthalates and 12 phenols. Results have been supervised by Doctor Miquel Porta, professor of Preventive Medicine and health and researcher at IMIM. He informed to all participants the results face to face and corroborated the faces of surprise and the impact of theparticipants.

    Més informació "Our health is increasingly conditioned and at risk from the proliferation of plastics that surround us, especially for food packaging (Press release by Rezero)"

  • 08/10/2019 - Press release

    Our own bodies hold the key to designing safer drugs

    Based on a study of 566 drugs that interact with 129 different proteins, researchers from the Systems Pharmacology research group, part of the GRIB Research Programme on Biomedical Informatics, a joint programme between the Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF), in collaboration with researchers from the University of New Mexico, in the United States, realised that 71% of drugs have stronger affinities for their target proteins than those of the small internal molecules responsible for regulating their functions. Surprisingly, this is the first time that the affinities of endogenous ligands and drugs for the same proteins have been quantified. Humans have thousands of proteins, each with a specific function that is often regulated by thousands of small molecules synthesised by our bodies. This set of small molecules, also known as "endogenous metabolites", is known as the "human metabolome". Each one interacts with its native protein with a certain affinity that has been carefully optimised, in a natural way, throughout the long process of evolution, and this can vary between species and even in some instances, more subtly, between individuals.

    Més informació "Our own bodies hold the key to designing safer drugs"

  • 23/08/2019 - Press release

    Effectiveness of a new bladder cancer treatment demonstrated

    Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment. The preliminary results of an ongoing clinical trial show that TAK-228, a mTORC1/2 protein inhibitor, can stop the progression of the disease. Four of the seven patients in the trial showed positive results. The trial also involved Hospital de la Santa Creu i Sant Pau in Barcelona, Hospital Universitari Parc Taulí in Sabadell, Clínica Universitaria in Navarre, and Hospital General Universitario in Elche.

    Més informació "Effectiveness of a new bladder cancer treatment demonstrated"

  • 10/07/2019 - Press release

    Mechanism determined for treating the most aggressive tumours

    A study led by researchers from the Hospital del Mar Medical Research Institute (IMIM), has determined, for the first time, the importance of a cell mechanism that may be key to treating metastatic tumours. The work has demonstrated the role a protein, kinase IKKα, plays in the ability of tumour cells to repair themselves. This is a key factor in treatment resistance and tumour spread. The research has been published in the journal Molecular Cell. The researchers analysed the role of this protein, activated by mutations of the BRAF and KRAS oncogenes, present in the majority of the most aggressive tumours. The function of this protein is to facilitate DNA-repair in tumour cells after they have been damaged by chemotherapy, making them more resistant to the action of these drugs. This is key for the treatment approach, since this new study demonstrates, conclusively, that combining a BRAF oncogene inhibitor with chemotherapy deactivates and kills the tumour.

    Més informació "Mechanism determined for treating the most aggressive tumours"

  • 28/06/2019 - Press release

    Possible marker of treatment resistance in HER2 breast cancer identified

    The ageing of NK lymphocytes circulating in the blood of patients with HER2-positive breast cancer is a marker that can predict the success or failure of monoclonal antibody therapies, which act on a specific factor in tumour cells.  This is the conclusion of a study led by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University, and doctors from the Hospital del Mar, published in the journal Cancer Immunology Research. The study also involved staff from the Medical Oncology Service at Hospital Clínic in Valencia, the Pathological Anatomy Services at Hospital del Mar, Fundación Jiménez Díaz in Madrid, and the Immunogenetics Service at Puerta de Hierro University Institute, also in Madrid. It involved analysing blood samples from 66 patients, immunogenetic and functional studies of the NK lymphocytes of these patients, as well as analysing tumour biopsies. The ageing of these cells was measured by quantifying the NK lymphocytes in the blood that express the CD57 molecule. The results show that patients with high blood counts at the time of diagnosis are more likely to be resistant to chemotherapy and anti-HER2 antibody treatment. 

    Més informació "Possible marker of treatment resistance in HER2 breast cancer identified"

Contact

Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

Tel:
(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact